《类风湿关节炎患者接受托珠单抗治疗12周时低基线白细胞介素-17A水平与更好的治疗反应相关》勘误
Erratum to "Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients".
作者信息
Lee Sang Jin, Park Won, Park Sung Hwan, Shim Seung-Cheol, Baek Han Joo, Yoo Dae-Hyun, Kim Hyun Ah, Lee Soo Kon, Lee Yun Jong, Park Young Eun, Cha Hoon-Suk, Park Jin Kyun, Lee Eun Young, Lee Eun Bong, Song Yeong Wook
机构信息
Division of Rheumatology, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Medical Research Institute, Seoul National University, Seoul, Republic of Korea.
出版信息
J Immunol Res. 2017;2017:7869412. doi: 10.1155/2017/7869412. Epub 2017 Aug 20.
Abstract
[This corrects the article DOI: 10.1155/2015/487230.].
摘要
[本文更正了文章的数字对象标识符：10.1155/2015/487230。]
相似文献
1
Erratum to "Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients".《类风湿关节炎患者接受托珠单抗治疗12周时低基线白细胞介素-17A水平与更好的治疗反应相关》勘误
J Immunol Res. 2017;2017:7869412. doi: 10.1155/2017/7869412. Epub 2017 Aug 20.
2
Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients.低基线白细胞介素-17A 水平与类风湿关节炎患者托珠单抗治疗 12 周时的治疗反应更好相关。
J Immunol Res. 2015;2015:487230. doi: 10.1155/2015/487230. Epub 2015 Apr 2.
3
Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.白细胞介素-1β水平可预测类风湿关节炎患者对托珠单抗治疗的反应：PETITE（托珠单抗治疗效果预测因素）研究
Rheumatol Int. 2016 Mar;36(3):349-57. doi: 10.1007/s00296-015-3379-x. Epub 2015 Oct 5.
4
[The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].托珠单抗联合改善病情抗风湿药治疗活动期类风湿关节炎的疗效和安全性：一项多中心、随机、双盲、安慰剂对照试验
Zhonghua Nei Ke Za Zhi. 2013 Apr;52(4):323-9.
5
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.托珠单抗抑制白细胞介素-6受体对类风湿关节炎患者的影响（OPTION研究）：一项双盲、安慰剂对照的随机试验。
Lancet. 2008 Mar 22;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5.
6
Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.托珠单抗治疗前后的血清白细胞介素 6 是类风湿关节炎患者的主要生物标志物。
J Rheumatol. 2013 Jul;40(7):1074-81. doi: 10.3899/jrheum.121389. Epub 2013 May 1.
7
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.使用托珠单抗抑制白细胞介素-6受体可降低对改善病情抗风湿药物反应不足的类风湿关节炎患者的疾病活动度：托珠单抗联合传统改善病情抗风湿药物治疗研究
Arthritis Rheum. 2008 Oct;58(10):2968-80. doi: 10.1002/art.23940.
8
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.托珠单抗、甲氨蝶呤或二者联合治疗早期类风湿关节炎（U-Act-Early）：一项多中心、随机、双盲、双模拟、策略试验。
Lancet. 2016 Jul 23;388(10042):343-355. doi: 10.1016/S0140-6736(16)30363-4. Epub 2016 Jun 7.
9
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.类风湿关节炎患者使用托珠单抗或阿达木单抗治疗后脂质及脂质相关心血管风险标志物变化的比较
Ann Rheum Dis. 2016 Oct;75(10):1806-12. doi: 10.1136/annrheumdis-2015-207872. Epub 2015 Nov 27.
10
The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.白介素-6 与其可溶性受体的结合与类风湿关节炎患者对托珠单抗的反应相关。
Semin Arthritis Rheum. 2018 Jun;47(6):757-764. doi: 10.1016/j.semarthrit.2017.10.022. Epub 2017 Nov 20.
本文引用的文献
1
Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients.低基线白细胞介素-17A 水平与类风湿关节炎患者托珠单抗治疗 12 周时的治疗反应更好相关。
J Immunol Res. 2015;2015:487230. doi: 10.1155/2015/487230. Epub 2015 Apr 2.
Zotero 插件